Expansion Includes New Growth Factor Receptor and Transcription Factor Assays Targeting Preclinical Oncology Research State College, PA (5 January 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include five new assays used primarily for preclinical oncology research. These cell-based in vitro assays include fourRead More
INDIGO’s Preclinical Animal Model Platform Expands Zebrafish Offering
Expansion Meets Industry Demand for Cell-Based Preclinical Models for Cancer, Chemical, and Environmental Research State College, PA (6 October 2020) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust portfolio of in vitro animal model assays with three additional first-in-class zebrafish model systems. Previously available only as a live-model system, INDIGO’sRead More
INDIGO Biosciences Announces Record Revenue for 2019
Company Shows Another Year of Record Growth and Advancements State College, PA (29 January 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, has announced a record earnings year for 2019. With final numbers to be released to Company Shareholders in the upcoming weeks,Read More
INDIGO Expands Discovery Platform to Include Zebrafish Assays
Expansion Meets Industry Demand for Pre-Clinical Models for Cancer and Environmental Research State College, PA (23 January 2020) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has announced the addition of four zebrafish assays to its portfolio. These additions both expand INDIGO’s robust portfolio of in vitro animal model assay systems andRead More